Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

被引:18
|
作者
Abuqbeitah, Mohammad [1 ]
Demir, Mustafa [1 ]
Uslu-Besli, Lebriz [1 ]
Yeyin, Nami [1 ]
Sonmezoglu, Kerim [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Fac Med, Dept Nucl Med, Istanbul, Turkey
关键词
Lu-177-DOTATATE; Lu-177-PSMA; Radiation exposure; Dose rate; Blood clearance; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR;
D O I
10.1007/s00411-017-0721-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The main target of this work is to examine blood clearance and external exposure for Lu-177-DOTATATE compared with new emerging Lu-177-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 +/- 1.1 GBq Lu-177-DOTATATE were compared to those of 23 patients treated with 7.4 GBq Lu-177-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to Lu-177-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 +/- 2.8 and 2 +/- 1.9 A mu Sv/(h GBq), respectively, while those due to Lu-177-PSMA were 3.1 +/- 0.8 and 2.2 +/- 0.9 A mu Sv/(h GBq). Total effective dose of 17 caregivers was 100-200 A mu Sv for Lu-177-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 A mu Sv per patient, respectively, while those for physicists and physicians were 2 A mu Sv per patient. For Lu-177-DOTATATE, effective half-life in blood and early elimination phase were 0.31 +/- 0.13 and 4.5 +/- 1 h, while they were found as 0.4 +/- 0.1 and 5 +/- 1 h, respectively, for Lu-177-PSMA. The first micturition time following Lu-177-DOTATATE infusion was noted after 36 +/- 14 min, while the second and third voiding times were after 74 +/- 9 and 128 +/- 41 min, respectively. It is concluded that blood clearance and radiation exposure for Lu-177-DOTATATE are very similar to those for Lu-177-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 A mu Sv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 A mu Sv/h) after 6 h at 1 m distance.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 21 条
  • [1] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Mohammad Abuqbeitah
    Mustafa Demir
    Lebriz Uslu-Beşli
    Nami Yeyin
    Kerim Sönmezoğlu
    Radiation and Environmental Biophysics, 2018, 57 : 55 - 61
  • [2] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [3] External dose assessment from the patients treated by 177Lu-DOTATATE
    Mahmoudi, E.
    Amoui, M.
    Deevband, M. R.
    Pirayesh, E.
    Rad, M. Ghorbani
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2022, 20 (01): : 235 - 239
  • [4] Safety and Efficacy of 177Lu-DOTATATE in Children and Young Adult Population
    Aggarwal, Piyush
    Satapathy, Swayamjeet
    Sood, Ashwani
    Singh, Harmandeep
    Mittal, Bhagwant Rai
    Lal, Sadhna
    Gupta, Rajesh
    Das, Chandan Krushna
    Yadav, Thakur Deen
    Walia, Rama
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : e312 - e318
  • [5] Evaluation of radiation safety in 177Lu-PSMA therapy and development of outpatient treatment protocol
    Demir, Mustafa
    Abuqbeitah, Mohammad
    Uslu-Besli, Lebriz
    Yildirim, Ozlem
    Yeyin, Nami
    Cavdar, Iffet
    Vatankulu, Betul
    Gunduz, Huseyin
    Kabasakal, Levent
    JOURNAL OF RADIOLOGICAL PROTECTION, 2016, 36 (02) : 269 - 278
  • [6] Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
    Zahed, Hanan
    Beauregard, Jean-Mathieu
    Abikhzer, Gad
    Rush, Christopher
    Probst, Stephan
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E12 - E15
  • [7] Patient external dose rate after 177Lu-DOTATATE therapy factors affecting its decrease and predictive value
    Zhang-Yin, Jules
    Guilabert, Nadine
    Kiffel, Thierry
    Montravers, Francoise
    Calais, Phillip
    Lumbroso, Jean
    Talbot, Jean-Noel
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (12): : 2725 - 2735
  • [8] Protection of Kidney Function with Human Antioxidation Protein α1-Microglobulin in a Mouse 177Lu-DOTATATE Radiation Therapy Model
    Kristiansson, Amanda
    Ahlstedt, Jonas
    Holmqvist, Bo
    Brinte, Anders
    Tran, Thuy A.
    Forssell-Aronsson, Eva
    Strand, Sven-Erik
    Gram, Magnus
    Akerstrom, Bo
    ANTIOXIDANTS & REDOX SIGNALING, 2019, 30 (14) : 1746 - 1759
  • [9] Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
    Liu, Fei
    Li, Panli
    Xu, Junyan
    Zhang, Jianping
    Xu, Xiaoping
    Chen, Zhihao
    Qiao, Ying
    Liang, Yun
    Chen, Jie
    Song, Shaoli
    EJNMMI RESEARCH, 2024, 14 (01):
  • [10] Radiation Dose to Medical Staff from Administering 177Lu-PSMA-DKFZ-617 Therapy
    Mahmoudi, Elahe
    Pirayesh, Elahe
    Deevband, Mohammad Reza
    Amoui, Mahasti
    Rad, Mohammadali Ghodsi
    Rad, Mehrdad Ghorbani
    Ghorbani, Mahdi
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 269 - 273